Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan:217:107663.
doi: 10.1016/j.pharmthera.2020.107663. Epub 2020 Aug 15.

Updates on community acquired pneumonia management in the ICU

Girish B Nair  1 , Michael S Niederman  2
Affiliations
Review

Updates on community acquired pneumonia management in the ICU

Girish B Nair et al. Pharmacol Ther. 2021 Jan.

Abstract

While the world is grappling with the consequences of a global pandemic related to SARS-CoV-2 causing severe pneumonia, available evidence points to bacterial infection with Streptococcus pneumoniae as the most common cause of severe community acquired pneumonia (SCAP). Rapid diagnostics and molecular testing have improved the identification of co-existent pathogens. However, mortality in patients admitted to ICU remains staggeringly high. The American Thoracic Society and Infectious Diseases Society of America have updated CAP guidelines to help streamline disease management. The common theme is use of timely, appropriate and adequate antibiotic coverage to decrease mortality and avoid drug resistance. Novel antibiotics have been studied for CAP and extend the choice of therapy, particularly for those who are intolerant of, or not responding to standard treatment, including those who harbor drug resistant pathogens. In this review, we focus on the risk factors, microbiology, site of care decisions and treatment of patients with SCAP.

Keywords: ATS/IDSA CAP guidelines; CAP severity assessment scores; New antibiotics; Severe community acquired pneumonia; Site of care.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest GN has no conflicts of interest with the published work. MN has received consultant support from Pfizer, Abbvie, Merck, Shionogi, and Thermo Fisher. He has received research support from Merck, Shiongi and Bayer.

Figures

Fig. 1
Fig. 1
Assessment and treatment of patients with severe community acquired pneumonia.
See this image and copyright information in PMC

References

    1. Barrera C.M., Mykietiuk A., Metev H., Nitu M.F., Karimjee N., Doreski P.A., Oldach D. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t] Lancet Infect. Dis. 2016;16(4):421–430. doi: 10.1016/S1473-3099(16)00017-7. - DOI - PubMed
    1. Adrie C., Schwebel C., Garrouste-Orgeas M., Vignoud L., Planquette B., Azoulay E.…Timsit J.F. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance. Crit. Care. 2013;17(6):R265. doi: 10.1186/cc13095. - DOI - PMC - PubMed
    1. Alexander E., Goldberg L., Das A.F., Moran G.J., Sandrock C., Gasink L.B.…Schranz J. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial. JAMA. 2019 doi: 10.1001/jama.2019.15468. - DOI - PMC - PubMed
    1. Aliberti S., Cook G.S., Babu B.L., Reyes L.F., A H.R., Sanz F., Restrepo M.I. International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia. [Research Support, U.S. Gov’t, Non-P.H.S.] J. Inf. Secur. 2019;79(4):300–311. doi: 10.1016/j.jinf.2019.07.004. - DOI - PubMed
    1. Aliberti S., Reyes L.F., Faverio P., Sotgiu G., Dore S., Rodriguez A.H.…Restrepo M.I. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. [Multicenter Study Observational Study] Lancet Infect. Dis. 2016;16(12):1364–1376. doi: 10.1016/S1473-3099(16)30267-5. - DOI - PubMed

Publication types

MeSH terms